Clinical Trial Update: Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events [Phase 3]

View source ↗

Summary

Phase 3 multicenter trial evaluating the effect of dapagliflozin on incidence of cardiovascular events in high-risk type 2 diabetes patients; trial completed wi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetes Mellitus Non-insulin-dependent
• High Risk For Cardiovascular Event

Drugs mentioned

• Dapagliflozin (dapagliflozin)

Snippet

Sponsor: AstraZeneca | Conditions: Diabetes Mellitus, Non-Insulin-Dependent, High Risk for Cardiovascular Event | Phase 3 | Status: COMPLETED | Results posted: 2019-12-26